RemeGen (9995) Q1 2026 earnings summary

Executive summary

• Operating revenue for Q1 2026 reached RMB 656.2 million, up 24.76% year-over-year, driven by increased sales of commercialized products and reduced R&D spending due to technology licensing.

• Net profit attributable to shareholders was RMB 328.0 million, reversing a net loss of RMB 254.1 million in Q1 2025.

• Basic and diluted EPS were RMB 0.58, compared to a loss per share of RMB -0.46 in the prior year.

Financial highlights

• Total assets increased to RMB 7.37 billion from RMB 7.25 billion at year-end 2025.

• Owners' equity attributable to shareholders rose to RMB 3.93 billion from RMB 3.61 billion.

• Net cash flows from operating activities improved to RMB 11.3 million from a negative RMB 188.3 million year-over-year.

• R&D spending decreased 36.19% year-over-year to RMB 209.9 million, now 31.98% of revenue.

Outlook and guidance

• Revenue growth is expected to continue, supported by strong sales of commercialized products and ongoing benefits from technology licensing.